New anti-VEGF agent could reduce treatment burden for patients with wet AMD


Novartis proprietary anti-VEGF agent RTH258 (brolucizumab) appears to be noninferior to aflibercept for treatment of neovascular age-related macular degeneration (AMD), according to results from 2 ongoing phase 3 studies.[Read More ] Source: Daily Dose of Eye Care
https://www.lvcenter4sight.com/new-anti-vegf-agent-could-reduce-treatment-burden-for-patients-with-wet-amd/

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s